C. Powers

Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study.

J. Lloyd-Still, C. Powers, D. Hoffman, 2006, Nutrition.

Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene

S. McColley, C. Powers, Manu Jain, 2016, Thorax.

Applied nutritional investigation Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study

J. Lloyd-Still, C. Powers, D. Hoffman, 2006 .

Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis

S. McColley, C. Powers, R. Seshadri, 2004, Journal of Clinical Microbiology.

Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection.

S. McColley, C. Powers, R. Seshadri, 2008, Translational research : the journal of laboratory and clinical medicine.

Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis

C. Powers, S. Johnson, JD Lloyd-Still, 1996, Acta paediatrica.

Carnitine metabolites in infants with cystic fibrosis: a prospective study

J. Lloyd-Still, C. Powers, H. Wessel, 1993, Acta paediatrica.

Carnitine metabolites in infants with cystic fibrosis.

J. Lloyd-Still, C. Powers, 1990, Acta Universitatis Carolinae. Medica.

Improved nutritional management reduces length of hospitalization in intractable diarrhea.

J. Lloyd-Still, C. Powers, A. E. Smith, 1986, JPEN. Journal of parenteral and enteral nutrition.

Cystic fibrosis in Asian Indians.

J. Lloyd-Still, C. Powers, E. M. Potter, 1996, Archives of pediatrics & adolescent medicine.